Zai Lab

Zai Lab

Dr. Samantha Du established Zai Lab in 2014, structuring it as a global biopharma from the outset with headquarters in both Shanghai and Cambridge, Massachusetts. The firm was built to translate scientific innovation into operating scale, supported by the experience of a team drawn from industry leaders across the United States, Greater China, and Europe. Zai Lab operates as a fully integrated company, combining internal R&D, clinical development, manufacturing, regulatory affairs, and a specialized commercial organization under one roof. Zai Lab's pipeline and commercial portfolio center on oncology, immunology, neuroscience, and infectious disease. The in-house R&D effort has progressed multiple global programs into clinical trials, including zocilurtatug pelitecan, a DLL3-targeted ADC for small cell lung cancer, and ZL-1503, a bispecific IL-13/IL-31 antibody for atopic dermatitis. A third program, ZL-6201, an LRRC15 ADC for solid tumors, is also advancing. On the commercial side, the firm's China portfolio holds eight marketed therapies, built in part through in-licensing agreements and partnerships with global biopharma companies. Zai Lab leverages its clinical trial infrastructure and commercial footprint across China, the second-largest pharmaceutical market globally, to accelerate market access for both partnered and internally developed assets. The firm maintains a multi-site operational footprint: R&D and commercial functions run from Shanghai, Beijing, and Suzhou; U.S. discovery and development teams operate from Cambridge, South San Francisco, and San Diego; and regional offices in Hong Kong and Taipei support Greater China distribution. Zai Lab has not publicly disclosed AUM or total deployment figures. As of its latest disclosures, the workforce and financial scale remain consolidated within the operating company rather than a fund structure. The company's end-to-end model — spanning early-stage discovery, small- and large-molecule manufacturing, and a field-based commercial team — gives it direct control over the development trajectory and economics of its pipeline. Zai Lab's structural signature is its dual-country operating company architecture rather than a traditional investment fund. The firm does not raise discrete venture funds; it allocates capital on a corporate balance sheet to in-license assets, fund internal R&D, and build physical infrastructure — its two manufacturing sites in China exemplify this model. Dr. Du remains the central decision-maker, and the company's Nasdaq listing provides a public-market lens into its capital allocation and commercial execution, a configuration rare among globally active development-stage biopharma platforms.